SCHEMBL1887619

SCHEMBL1887619

C[Si]1(C)CC[Si](C)(C)N1c1ccc(C(O)c2cn(S(=O)(=O)c3ccccc3)c3ncc(Cl)cc23)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.39
CNR1 P21554 3/20 0.33
CYP3A4 P08684 2/20 0.33
DRD2 P14416 1/20 0.33
SLC6A2 P23975 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR7 P34969 1/20 0.33
HRH1 P35367 1/20 0.33
ADRA1B P35368 1/20 0.33
SLC6A3 Q01959 1/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
HTR6 P50406 1/20 0.32
KDM1A O60341 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1887236 0.82 BRD4 (0.41) BRD4CYP3A4DRD2SLC6A2HTR2A
SCHEMBL1268028 0.79 BRD4 (0.41) BRD4CYP3A4DRD2SLC6A2HTR2A
SCHEMBL12252453 0.75 BRD4 (0.35) BRD4CYP3A4HTR6CYP3A5
SCHEMBL19302282 0.74 ABL1 (0.35) BRD4CYP3A4SLC6A2SLC6A3ALDH1A1
SCHEMBL1268407 0.70 ATM (0.34) BRD4ALDH1A1SMN1; SMN2NPSR1
SCHEMBL15607451 0.68 BRD4 (0.43) BRD4CYP3A4DRD2SLC6A2HTR2A
SCHEMBL1266871 0.68 BRD4 (0.58) BRD4CYP3A4DRD2SLC6A2HTR2A
SCHEMBL1268061 0.66 KDM4E (0.45) BRD4CYP3A4DRD2SLC6A2HTR2A
SCHEMBL1268320 0.66 LCK (0.36) BRD4CYP3A4DRD2SLC6A2HTR2A
SCHEMBL1267507 0.66 HTR6 (0.38) BRD4CYP3A4ALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
EP-2496086-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Plexxikon, Inc. (US) 2012-09-12 EP disclosed
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF BRD4 3163/4885CNR1 4211/4885CYP3A4 3717/4885
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF BRD4 3163/4885CNR1 4211/4885CYP3A4 3717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.